UPM to Manufacture Products For Amerigen Pharmaceuticals

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-05-07-2014
Volume 10
Issue 5

UPM will commercially manufacture two ANDA products for Amerigen Pharmaceuticals.

UPM, a division of Gregory Pharmaceutical Holdings, has reached an agreement with Amerigen Pharmaceuticals, to commercially manufacture two ANDA products for a 10-year supply term. In addition, the agreement allows for UPM to develop and potentially commercially supply several additional ANDA products for Amerigen over the next few years. UPM acquired a 475,000 ft2 Pfizer manufacturing facility in Bristol, Tennessee in July of 2013, that will supply these products.

Source: UPM

Articles in this issue
Web-Kurt-Lumsden-842476-1408522400909.png
Using eClinical Systems for Supply-Chain Management
Janssen Pharmaceutical Collaborates with Stiching International Dispensary Association
Wechsler_Jill-842477-1408522399381.jpg
FDA and Industry Take Action for a More Secure Drug Supply Chain
Packaging Becomes Enabler for Biopharmaceuticals
Bristol-Myers Squibb Named First on 2014 Best Corporate Citizens List
Azzur Group and BioSPEQ Announce Merger
Eli Lilly Launches Second Education Program for Medical Students
Global Instability Impacts Brazil's Pharma Market
Global Instability Impacts Brazil's Pharma Market
peters_rita-842486-1408522392330.jpg
US Biopharma Worries About Losing Lead in Innovation
Eric_Langer_Headshot-842478-1408522397462.jpg
Outsourcing Remains Strong In Traditional Areas
Process Design Is Critical for Commercial Manufacture of HPAPIs
Process Design Is Critical for Commercial Manufacture of HPAPIs
Novartis Publishes eBook of Meningococcal Disease Survivors
Gallus BioPharmaceuticals Enters Agreement with Omni Bio Pharmaceutical
Colorcon Opens Major Facility in India
Capsugel Enters Agreement with Chiasma to Manufacture Oral Octreotide Acetate
Recent Videos
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Sanofi Grows Antibody Production in France with €40 Million Investment

Feliza Mirasol
November 22nd 2024
Article

Sanofi will use this investment to increase its antibody bioproduction at its site in Lyon Gerland, France.

Drug Solutions Podcast: Examining the State of Biopharma Investment

Drug Solutions Podcast: Examining the State of Biopharma Investment

Grant Playter
June 6th 2023
Podcast

In this episode, Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

CDMO SEKISUI Expands its CGMP Biopharma Manufacturing Capacity

Feliza Mirasol
November 20th 2024
Article

SEKISUI has used a £15.7 million (US$20.7 million) investment to expand its clinical-grade drug substance manufacturing at its UK site.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Alentis Therapeutics to Advance Anti-Claudin-1 ADCs to Treat Solid Tumors on $181.4 Million Financing

Feliza Mirasol
November 19th 2024
Article

Financing from OrbiMed, Novo Holdings, Jeito Capital, and others will enable Alentis Therapeutics to advance its pipeline of Claudin-1-targeted ADCs for treating solid tumors.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Avantor Sees Future of Opportunities with Growing Development of Next-Gen Biotherapeutics

Feliza Mirasol
November 15th 2024
Article

Executives at Avantor talk about the future of the biopharmaceutical industry and the anticipated impact that a wave of next-generation biotherapeutics will bring.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Merck and Ginkgo Bioworks’ Collaboration to Improve Biologics Manufacturing Has Reached Its First Milestone

Feliza Mirasol
November 13th 2024
Article

Under an ongoing partnership with Merck, known as MSD outside of the United States and Canada, Ginkgo Bioworks has achieved the first milestone in a project aimed at improving biologics production.